Literature DB >> 8276464

Upmodulation by estrogen of HLA class I expression in breast tumor cell lines.

F Rodríguez1, F Perán, F Garrido, F Ruiz-Cabello.   

Abstract

The expression of major histocompatibility complex (MHC) class I antigens was studied in five breast carcinoma cell lines before and after treatment with 17-beta estradiol. Increased HLA class I antigen expression correlated with the presence of estrogen receptors. The modulation of expression appeared to be mediated by transcriptional mechanisms, as revealed by class I mRNA levels. To elucidate the basis of MHC class I upregulation, we examined transcriptional factor binding activity to the class I regulatory element (CRE). Our results showed that 17-beta estradiol induced increases in factor binding activity to the CRE II probe, and decreases to the CRE I probe. In addition, our results suggested that factors that bind the CRE I region may modulate the binding of CRE II. Binding to CRE II was significantly increased in extracts pretreated with a competitor that contained the CRE I sequence, and that bound NF-kB/kBF1. In addition, induction of NF-kB binding activity by the tumor necrosis factor was accompanied by a decrease in nuclear factors that bind to the CRE II region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8276464     DOI: 10.1007/bf00241256

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  27 in total

Review 1.  Regulation of the expression of class I MHC genes.

Authors:  D S Singer; J E Maguire
Journal:  Crit Rev Immunol       Date:  1990       Impact factor: 2.214

Review 2.  The inducible transcription activator NF-kappa B: regulation by distinct protein subunits.

Authors:  P A Baeuerle
Journal:  Biochim Biophys Acta       Date:  1991-04-16

Review 3.  The regulation and expression of MHC class I genes.

Authors:  B David-Watine; A Israël; P Kourilsky
Journal:  Immunol Today       Date:  1990-08

Review 4.  Commitment and activation at pol II promoters: a tail of protein-protein interactions.

Authors:  B Lewin
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

5.  Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence.

Authors:  Y Shirayoshi; P A Burke; E Appella; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.

Authors:  G C Reiner; B S Katzenellenbogen
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

7.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

8.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

9.  Modulation of MHC gene expression in human breast carcinoma cells by hormones.

Authors:  M Teh; K M Hui
Journal:  J Immunogenet       Date:  1989 Aug-Oct

10.  Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters.

Authors:  M Redondo; A Concha; R Oldiviela; A Cueto; A Gonzalez; F Garrido; F Ruiz-Cabello
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

View more
  1 in total

Review 1.  Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Authors:  Aura Muntasell; Mariona Cabo; Sonia Servitja; Ignasi Tusquets; María Martínez-García; Ana Rovira; Federico Rojo; Joan Albanell; Miguel López-Botet
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.